Latest mental health news
WEDNESDAY, January 22, 2020 (HealthDay News) – The buprenorphin opioid drug treatment is on the rise in most age groups in the United States, but falls between the ages of 15 and 24, a new study for see.
Dr Mark Olfson, who led the study, said: "While it is encouraging to see an increase in the prescribing rate for buprenorphin, the data shows that the youngest group is having difficulty accessing treatment. could save this life ". He is a professor of psychiatry, medicine and law at the College of Physicians and Surgeons in New York City.
"These findings for young people are particularly worrying, because their decrease in buprenorphin treatment occurs during the period when there is an increase in mortality from opioid overdose for this age group," Olfson said in A new university newsletter.
Buprenorphin is a treatment approved by the US Food and Drug Administration for opioid addiction. Analysis of national data shows that its total usage more than doubled from 2009 to 2018 – from 1.97 per 1,000 people to 4.43 per 1,000 people.
However, drug use decreased by about 20% in the youngest group – from 1.76 to 1.40 per 1,000 people.
The duration of buprenorphin treatment and prescription strength is also lower in people aged 15 to 24 years than older Americans, findings suggest.
There are famous barriers to get …